[HTML][HTML] Structural basis of nSH2 regulation and lipid binding in PI3Kα

MS Miller, O Schmidt-Kittler, DM Bolduc, ET Brower… - Oncotarget, 2014 - ncbi.nlm.nih.gov
MS Miller, O Schmidt-Kittler, DM Bolduc, ET Brower, D Chaves-Moreira, M Allaire…
Oncotarget, 2014ncbi.nlm.nih.gov
We report two crystal structures of the wild-type phosphatidylinositol 3-kinase α (PI3Kα)
heterodimer refined to 2.9 Å and 3.4 Å resolution: the first as the free enzyme, the second in
complex with the lipid substrate, diC4-PIP 2, respectively. The first structure shows key
interactions of the N-terminal SH2 domain (nSH2) and iSH2 with the activation loop that
suggest a mechanism by which the enzyme is inhibited in its basal state. In the second
structure, the lipid substrate binds in a positively charged pocket adjacent to the ATP-binding …
Abstract
We report two crystal structures of the wild-type phosphatidylinositol 3-kinase α (PI3Kα) heterodimer refined to 2.9 Å and 3.4 Å resolution: the first as the free enzyme, the second in complex with the lipid substrate, diC4-PIP 2, respectively. The first structure shows key interactions of the N-terminal SH2 domain (nSH2) and iSH2 with the activation loop that suggest a mechanism by which the enzyme is inhibited in its basal state. In the second structure, the lipid substrate binds in a positively charged pocket adjacent to the ATP-binding site, bordered by the P-loop, the activation loop and the iSH2 domain. An additional lipid-binding site was identified at the interface of the ABD, iSH2 and kinase domains. The ability of PI3Kα to bind an additional PIP 2 molecule was confirmed in vitro by fluorescence quenching experiments. The crystal structures reveal key differences in the way the nSH2 domain interacts with wild-type p110α and with the oncogenic mutant p110αH1047R. Increased buried surface area and two unique salt-bridges observed only in the wild-type structure suggest tighter inhibition in the wild-type PI3Kα than in the oncogenic mutant. These differences may be partially responsible for the increased basal lipid kinase activity and increased membrane binding of the oncogenic mutant.
ncbi.nlm.nih.gov